2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Top Cited Papers
Open Access
- 1 January 2020
- journal article
- review article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 79 (1), 19-30
- https://doi.org/10.1136/annrheumdis-2019-215672
Abstract
Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations. Methods Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 13 countries. We modified existing recommendations and created new recommendations. Results Three overarching principles and 10 recommendations were formulated. We recommend that a suspected diagnosis of LVV should be confirmed by imaging or histology. High dose glucocorticoid therapy (40-60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active giant cell arteritis (GCA) or Takayasu arteritis (TAK). We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using tocilizumab. Methotrexate may be used as an alternative. Non-biological glucocorticoid-sparing agents should be given in combination with glucocorticoids in all patients with TAK and biological agents may be used in refractory or relapsing patients. We no longer recommend the routine use of antiplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for other reasons. Conclusions We have updated the recommendations for the management of LVV to facilitate the translation of current scientific evidence and expert opinion into better management and improved outcome of patients in clinical practice.Keywords
Funding Information
- European League Against Rheumatism (CLI099)
This publication has 121 references indexed in Scilit:
- Recovery of Adrenal Function after Long-Term Glucocorticoid Therapy for Giant Cell Arteritis: A Cohort StudyPLOS ONE, 2013
- Design of the Tocilizumab in Giant Cell Arteritis TrialInternational Journal of Rheumatology, 2013
- Utility of Erythrocyte Sedimentation Rate and C-Reactive Protein for the Diagnosis of Giant Cell ArteritisSeminars in Arthritis and Rheumatism, 2012
- Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long‐term followupArthritis Care & Research, 2012
- Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-upAnnals Of The Rheumatic Diseases, 2008
- Quality of life of patients with Takayasu’s arteritisJournal of Vascular Surgery, 2008
- EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitisAnnals Of The Rheumatic Diseases, 2007
- Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritisClinical Rheumatology, 2007
- Takayasu’s arteritis: Operative results and influence of disease activityJournal of Vascular Surgery, 2006
- Steroid management in giant cell arteritisBritish Journal of Ophthalmology, 2001